ORIGINAL ARTICLE
G84E germline mutation in HOXB13 gene is associated with increased prostate cancer risk in Polish men
1
Department of Clinical Genetics, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruñ, Poland
2
Department of Urology, Jan Biziel University Hospital in Bydgoszcz, Poland
Submission date: 2018-08-28
Final revision date: 2018-12-21
Acceptance date: 2018-12-23
Publication date: 2019-09-03
Pol J Pathol 2019;70(2):127-133
KEYWORDS
TOPICS
ABSTRACT
We tested the association between HOXB13 G84E (rs138213197) germline mutation and PC risk in Polish men.
DNA from 103 consecutive, newly diagnosed patients hospitalised because of PC and DNA from 103 men: volunteers, healthy at the time of the study.
The G84E mutation was genotyped using Sanger sequencing.
The HOXB13 G84E germline mutation was detected in 2.9% of PC men (3/103) and not detected in any healthy man. Two mutation carriers originated from two of 25 families fulfilling hereditary prostate cancer criteria (HPC) and one mutation carrier from one family among 78 families without HPC (PC frequency: 8% vs. 1.3%, OR = 6.70, p = 0.13). In two of three mutation carriers, disease was detected above 60 years of age. There was a trend for a lower probability of 5-year survival in patients with G84E than in patients without it (66.7% vs. 94.0%, p = 0.08).
The HOXB13 G84E germline mutation is associated with increased prostate cancer risk in Polish men, with hereditary form of the disease, and probably with older age at PC onset (> 60 years of age) and shorter survival. However, it is not associated with PSA level, or PC stage or grade at the time of diagnosis.
DNA from 103 consecutive, newly diagnosed patients hospitalised because of PC and DNA from 103 men: volunteers, healthy at the time of the study.
The G84E mutation was genotyped using Sanger sequencing.
The HOXB13 G84E germline mutation was detected in 2.9% of PC men (3/103) and not detected in any healthy man. Two mutation carriers originated from two of 25 families fulfilling hereditary prostate cancer criteria (HPC) and one mutation carrier from one family among 78 families without HPC (PC frequency: 8% vs. 1.3%, OR = 6.70, p = 0.13). In two of three mutation carriers, disease was detected above 60 years of age. There was a trend for a lower probability of 5-year survival in patients with G84E than in patients without it (66.7% vs. 94.0%, p = 0.08).
The HOXB13 G84E germline mutation is associated with increased prostate cancer risk in Polish men, with hereditary form of the disease, and probably with older age at PC onset (> 60 years of age) and shorter survival. However, it is not associated with PSA level, or PC stage or grade at the time of diagnosis.
REFERENCES (33)
1.
Hemminki K, Czene K. Age specific and attributable risks of familial prostate carcinoma from the family-cancer database. Cancer 2002; 95: 1346-1353.
2.
Zeegers MP, Jellema A, Ostrer H. Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a meta-analysis. Cancer 2003; 97: 1894-1903.
3.
Schab M, Janiszewska H, Jarzemski P, et al. Frequency of CYP1B1 homozygous genotype 355T/T in prostate cancer families from Poland. Eur J Cancer Prev 2010; 19: 31-34.
4.
Hjelmborg JB, Scheike T, Holst K, et al. The heritability of prostate cancer in the Nordic Twin Study of Cancer. Cancer Epidemiol Biomarkers Prev 2014; 23: 2303-2310.
5.
Tavtigian SV, Simard J, Teng DH, et al. A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet 2001; 27: 172-180.
6.
Wang L, McDonnell SK, Elkins DA, et al. Role of HPC2/ELAC2 in hereditary prostate cancer. Cancer Res 2001; 61: 6494-6499.
7.
Xu J, Zheng SL, Carpten JD, et al. Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer. Am J Hum Genet 2001; 68: 901-911.
8.
Carpten J, Nupponen N, Isaacs S, et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 2002; 3: 181-418.
9.
Xu J, Zheng SL, Komiya A, et al. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet 2002; 32: 321-325.
10.
Rennert H, Zeigler-Johnson CM, Addya K, et al. Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men. Cancer Epidemiol Biomarkers Prev 2005; 14: 949-957.
11.
Cybulski C, Gliniewicz B, Sikorski A, et al. Hereditary prostate cancer: Clinical genetics of cancers 2017. Lubiñski J (ed.). Print Group, Poland 2017; 177-190.
12.
Dong X, Wang L, Taniguchi K, et al. Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet 2003; 72: 270-280.
13.
Cybulski C, Górski B, Dêbniak T, et al. NBS1 is a prostate cancer susceptibility gene. Cancer Res 2004; 64: 1215-1219.
14.
Cybulski C, Huzarski T, Górski B, et al. A novel founder CHEK2 mutation is associated with increased prostate cancer risk. Cancer Res 2004; 64: 2677-2679.
15.
Kote-Jarai Z, Leongamornlert D, Saunders E, et al. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer 2011; 105: 1230-1234.
16.
Leongamornlert D, Mahmud N, Tymrakiewicz M, et al. Germline BRCA1 mutations increase prostate cancer risk. Br J Cancer 2012; 106: 1697-1701.
17.
Goh CL, Schumacher FR, Easton D, et al. Genetic variants associated with predisposition to prostate cancer and potential clinical implications. J Intern Med 2012; 271: 353-365.
18.
Eeles RA, Olama AA, Benlloch S, et al. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet 2013; 45: 385-391.
19.
Kote-Jarai Z, Mikropoulos C, Leongamornlert DA, et al. Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes. Ann Oncol 2015; 26: 756-761.
20.
Ewing CM, Ray AM, Lange EM, et al. Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med 2012; 366: 141-149.
21.
Akbari MR, Trachtenberg J, Lee J, et al. Association between germline HOXB13 G84E mutation and risk of prostate cancer. J Natl Cancer Inst 2012; 104: 1260-1262.
22.
Laitinen VH, Wahlfors T, Saaristo L, et al. HOXB13 G84E mutation in Finland: population-based analysis of prostate, breast, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2013; 22: 452-460.
23.
Decker B, Ostrander EA. Dysregulation of the homeobox transcription factor gene HOXB13: role in prostate cancer. Pharmgenomics Pers Med 2014; 7: 193-201.
24.
Cai Q, Wang X, Li X, et al. Germline HOXB13 p.Gly84Glu mutation and cancer susceptibility: a pooled analysis of 25 epidemiological studies with 145,257 participates. Oncotarget 2015; 6: 42312-42321.
25.
Sipeky C, Gao P, Zhang Q, et al. Synergistic interaction of HOXB13 and CIP2A predisposes to aggressive prostate cancer. Clin. Cancer Res 2018; doi: 10.1158/1078-0432.CCR-18-0444.
26.
Breyer JP, Avritt TG, McReynolds KM, et al. Confirmation of the HOXB13 G84E germline mutation in familial prostate cancer. Cancer Epidemiol Biomarkers Prev 2012; 21: 1348-1353.
27.
KluŸniak W, Woko³orczyk D, Kashyap A, et al. The G84E mutation in the HOXB13 gene is associated with an increased risk of prostate cancer in Poland. Prostate 2013; 73: 542-548.
28.
Stott-Miller M, Karyadi DM, Smith T, et al. HOXB13 mutations in a population-based, case-control study of prostate cancer. Prostate 2013; 73: 634-641.
29.
Karlsson R, Aly M, Clements M, et al. A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk. Eur Urol 2014; 65: 169-176.
30.
Lin X, Qu L, Chen Z, et al. A novel germline mutation in HOXB13 is associated with prostate cancer risk in Chinese men. Prostate 2013; 73: 169-175.
31.
Carter BS, Bova GS, Beaty TH, et al. Hereditary prostate cancer: epidemiologic and clinical features. J Urol 1993; 150: 797-802.
32.
Storebjerg TM, Hoyer S, Kirkegaard P, et al. Prevalence of the HOXB13 G84E mutation in Danish men undergoing radical prostatectomy and its correlations with prostate cancer risk and aggressiveness. BJU Int 2016; 118: 646-653.
33.
Chen H, Ewing CM, Zheng S, et al. Genetic factors influencing prostate cancer risk in Norwegian men. Prostate 2018; 78: 186-192.
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
